Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control.
Malnati MS, Ugolotti E, Monti MC, Battista D, Vanni I, Bordo D, Sironi F, Larghero P, Marco ED, Biswas P, Poli G, Vicenzi E, Riva A, Tarkowski M, Tambussi G, Nozza S, Tripodi G, Marras F, De Maria A, Pistorio A, Biassoni R. Malnati MS, et al. Among authors: tambussi g. Sci Rep. 2017 Feb 13;7:42470. doi: 10.1038/srep42470. Sci Rep. 2017. PMID: 28211903 Free PMC article.
B-cell subset alterations and correlated factors in HIV-1 infection.
Pensieroso S, Galli L, Nozza S, Ruffin N, Castagna A, Tambussi G, Hejdeman B, Misciagna D, Riva A, Malnati M, Chiodi F, Scarlatti G. Pensieroso S, et al. Among authors: tambussi g. AIDS. 2013 May 15;27(8):1209-17. doi: 10.1097/QAD.0b013e32835edc47. AIDS. 2013. PMID: 23343911
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, Brambilla A, Vicenzi E, Carrera P, Racca S, Soldini L, Gianotti N, Murone M, Veglia F, Poli G, Lazzarin A. Tambussi G, et al. J Infect Dis. 2001 May 15;183(10):1476-84. doi: 10.1086/320188. Epub 2001 Apr 13. J Infect Dis. 2001. PMID: 11319683 Clinical Trial.
Oral CCR5 inhibitors: will they make it through?
Biswas P, Nozza S, Scarlatti G, Lazzarin A, Tambussi G. Biswas P, et al. Among authors: tambussi g. Expert Opin Investig Drugs. 2006 May;15(5):451-64. doi: 10.1517/13543784.15.5.451. Expert Opin Investig Drugs. 2006. PMID: 16634684 Review.
208 results